Do analysts recommend INMB or IMUX?

Immunic has a consensus target price of $47.57, suggesting a potential upside of 213.90%. Given Immunic's stronger consensus rating and higher probable upside, analysts clearly believe Immunic is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Immunic 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.00

Which has higher earnings and valuation, INMB or IMUX?

INmune Bio has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INmune Bio $50K 1,039.28 -$45.93M -$1.67 N/A Immunic N/A N/A -$97.17M -$5.58 N/A

Is INMB or IMUX more profitable?

INmune Bio's return on equity of -103.03% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -103.03% -77.66% Immunic N/A -220.75% -132.04%

Do analysts prefer NERV or INMB?

Minerva Neurosciences presently has a consensus target price of $10.50, indicating a potential upside of 132.56%. Given Minerva Neurosciences' higher possible upside, equities analysts clearly believe Minerva Neurosciences is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is NERV or INMB more profitable?

Minerva Neurosciences' return on equity of 0.00% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -32.63% INmune Bio N/A -103.03% -77.66%

Do analysts prefer NKTX or INMB?

Nkarta currently has a consensus target price of $10.75, suggesting a potential upside of 317.48%. Given Nkarta's stronger consensus rating and higher probable upside, equities research analysts clearly believe Nkarta is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nkarta 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better valuation and earnings, NKTX or INMB?

INmune Bio has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.34 N/A INmune Bio $50K 1,039.28 -$45.93M -$1.67 N/A

Is NKTX or INMB more profitable?

Nkarta's return on equity of -30.90% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -30.90% -24.20% INmune Bio N/A -103.03% -77.66%

Does the media favor NKTX or INMB?

In the previous week, Nkarta and Nkarta both had 3 articles in the media. Nkarta's average media sentiment score of 0.59 beat INmune Bio's score of -0.61 indicating that Nkarta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nkarta 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Do analysts rate ABOS or INMB?

Acumen Pharmaceuticals presently has a consensus price target of $8.00, indicating a potential upside of 259.55%. Given Acumen Pharmaceuticals' higher possible upside, equities research analysts clearly believe Acumen Pharmaceuticals is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acumen Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is ABOS or INMB more profitable?

INmune Bio's return on equity of -103.03% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -123.07% -79.41% INmune Bio N/A -103.03% -77.66%

Does the media favor ABOS or INMB?

In the previous week, Acumen Pharmaceuticals had 1 more articles in the media than INmune Bio. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 3 mentions for INmune Bio. Acumen Pharmaceuticals' average media sentiment score of 0.33 beat INmune Bio's score of -0.61 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Do analysts recommend INMB or PLX?

Protalix BioTherapeutics has a consensus target price of $12.00, indicating a potential upside of 407.40%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

INmune Bio (INMB) Competitors

$1.96 -0.04 (-1.76%)

As of 03:49 PM Eastern

Compare

INMB vs. IMUX, NERV, NKTX, ABOS, and PLX

Should you buy INmune Bio stock or one of its competitors? MarketBeat compares INmune Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with INmune Bio include Immunic (IMUX), Minerva Neurosciences (NERV), Nkarta (NKTX), Acumen Pharmaceuticals (ABOS), and Protalix BioTherapeutics (PLX). These companies are all part of the "pharmaceutical products" industry.

How does INmune Bio compare to Immunic?

INmune Bio (NASDAQ:INMB) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

In the previous week, INmune Bio had 3 more articles in the media than Immunic. MarketBeat recorded 3 mentions for INmune Bio and 0 mentions for Immunic. Immunic's average media sentiment score of 0.00 beat INmune Bio's score of -0.61 indicating that Immunic is being referred to more favorably in the news media.

Company	Overall Sentiment
INmune Bio	Negative
Immunic	Neutral

INmune Bio has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,039.28	-$45.93M	-$1.67	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

INmune Bio has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Immunic has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by insiders. Comparatively, 5.5% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

INmune Bio's return on equity of -103.03% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Immunic	N/A	-220.75%	-132.04%

Immunic has a consensus target price of $47.57, suggesting a potential upside of 213.90%. Given Immunic's stronger consensus rating and higher probable upside, analysts clearly believe Immunic is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

INmune Bio beats Immunic on 8 of the 15 factors compared between the two stocks.

How does INmune Bio compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

In the previous week, INmune Bio had 3 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for INmune Bio and 0 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.00 beat INmune Bio's score of -0.61 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Minerva Neurosciences	Neutral
INmune Bio	Negative

Minerva Neurosciences has a beta of -0.16, indicating that its stock price is 116% less volatile than the broader market. Comparatively, INmune Bio has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Minerva Neurosciences presently has a consensus target price of $10.50, indicating a potential upside of 132.56%. Given Minerva Neurosciences' higher possible upside, equities analysts clearly believe Minerva Neurosciences is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

INmune Bio has higher revenue and earnings than Minerva Neurosciences. INmune Bio is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
INmune Bio	$50K	1,039.28	-$45.93M	-$1.67	N/A

Minerva Neurosciences' return on equity of 0.00% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
INmune Bio	N/A	-103.03%	-77.66%

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by insiders. Comparatively, 21.4% of INmune Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

INmune Bio beats Minerva Neurosciences on 8 of the 15 factors compared between the two stocks.

How does INmune Bio compare to Nkarta?

Nkarta (NASDAQ:NKTX) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Nkarta currently has a consensus target price of $10.75, suggesting a potential upside of 317.48%. Given Nkarta's stronger consensus rating and higher probable upside, equities research analysts clearly believe Nkarta is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

INmune Bio has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
INmune Bio	$50K	1,039.28	-$45.93M	-$1.67	N/A

Nkarta's return on equity of -30.90% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
INmune Bio	N/A	-103.03%	-77.66%

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 9.8% of Nkarta shares are owned by insiders. Comparatively, 21.4% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Nkarta has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, INmune Bio has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

In the previous week, Nkarta and Nkarta both had 3 articles in the media. Nkarta's average media sentiment score of 0.59 beat INmune Bio's score of -0.61 indicating that Nkarta is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Summary

Nkarta beats INmune Bio on 8 of the 13 factors compared between the two stocks.

How does INmune Bio compare to Acumen Pharmaceuticals?

Acumen Pharmaceuticals (NASDAQ:ABOS) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Acumen Pharmaceuticals presently has a consensus price target of $8.00, indicating a potential upside of 259.55%. Given Acumen Pharmaceuticals' higher possible upside, equities research analysts clearly believe Acumen Pharmaceuticals is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

INmune Bio's return on equity of -103.03% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
INmune Bio	N/A	-103.03%	-77.66%

Acumen Pharmaceuticals has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, INmune Bio has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

INmune Bio has higher revenue and earnings than Acumen Pharmaceuticals. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
INmune Bio	$50K	1,039.28	-$45.93M	-$1.67	N/A

In the previous week, Acumen Pharmaceuticals had 1 more articles in the media than INmune Bio. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 3 mentions for INmune Bio. Acumen Pharmaceuticals' average media sentiment score of 0.33 beat INmune Bio's score of -0.61 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 10.2% of Acumen Pharmaceuticals shares are held by company insiders. Comparatively, 21.4% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

INmune Bio beats Acumen Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does INmune Bio compare to Protalix BioTherapeutics?

INmune Bio (NASDAQ:INMB) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by company insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

INmune Bio has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Protalix BioTherapeutics has a consensus target price of $12.00, indicating a potential upside of 407.40%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Protalix BioTherapeutics has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,039.28	-$45.93M	-$1.67	N/A
Protalix BioTherapeutics	$76.38M	2.49	$8.31M	$0.18	13.14

In the previous week, INmune Bio had 3 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 3 mentions for INmune Bio and 0 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 0.00 beat INmune Bio's score of -0.61 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
INmune Bio	Negative
Protalix BioTherapeutics	Neutral

Summary

Protalix BioTherapeutics beats INmune Bio on 10 of the 16 factors compared between the two stocks.

Get INmune Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INMB vs. The Competition

Export

Metric	INmune Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$51.96M	$3.65B	$6.81B	$12.43B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-1.17	20.73	26.98	24.19
Price / Sales	1,039.28	323.20	519.35	94.24
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	2.22	8.18	10.67	6.26
Net Income	-$45.93M	$23.81M	$3.60B	$331.76M
7 Day Performance	-3.22%	-1.43%	-0.54%	-1.21%
1 Month Performance	34.83%	2.31%	1.66%	-1.35%
1 Year Performance	-17.86%	44.96%	25.11%	18.68%

INmune Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INMB INmune Bio	0.811 of 5 stars	$1.96 -1.8%	N/A	-17.8%	$51.96M	$50K	N/A	10
IMUX Immunic	2.6697 of 5 stars	$14.86 +1.5%	$47.57 +220.2%	+55.6%	$202.53M	N/A	N/A	70
NERV Minerva Neurosciences	1.7278 of 5 stars	$4.31 +0.8%	$10.50 +143.9%	+115.8%	$200.62M	N/A	N/A	9	Positive News
NKTX Nkarta	3.7539 of 5 stars	$2.78 -0.3%	$10.75 +286.6%	+34.6%	$199.95M	N/A	N/A	140
ABOS Acumen Pharmaceuticals	2.4548 of 5 stars	$2.74 +3.6%	$8.00 +192.4%	+47.3%	$197.98M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INMB) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

INmune Bio (INMB) Competitors

INMB vs. IMUX, NERV, NKTX, ABOS, and PLX

How does INmune Bio compare to Immunic?

Summary

How does INmune Bio compare to Minerva Neurosciences?

Summary

How does INmune Bio compare to Nkarta?

Summary

How does INmune Bio compare to Acumen Pharmaceuticals?

Summary

How does INmune Bio compare to Protalix BioTherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

INmune Bio (INMB) Competitors

INMB vs. IMUX, NERV, NKTX, ABOS, and PLX

How does INmune Bio compare to Immunic?

Does the media prefer INMB or IMUX?

Which has higher earnings and valuation, INMB or IMUX?

Which has more risk and volatility, INMB or IMUX?

Do insiders and institutionals have more ownership in INMB or IMUX?

Is INMB or IMUX more profitable?

Do analysts recommend INMB or IMUX?

Summary

How does INmune Bio compare to Minerva Neurosciences?

Does the media refer more to NERV or INMB?

Which has more volatility & risk, NERV or INMB?

Do analysts prefer NERV or INMB?

Which has higher earnings & valuation, NERV or INMB?

Is NERV or INMB more profitable?

Do institutionals and insiders believe in NERV or INMB?

Summary

How does INmune Bio compare to Nkarta?

Do analysts prefer NKTX or INMB?

Which has better valuation and earnings, NKTX or INMB?

Is NKTX or INMB more profitable?

Do insiders & institutionals hold more shares of NKTX or INMB?

Which has more volatility and risk, NKTX or INMB?

Does the media favor NKTX or INMB?

Summary

How does INmune Bio compare to Acumen Pharmaceuticals?

Do analysts rate ABOS or INMB?

Is ABOS or INMB more profitable?

Which has more risk & volatility, ABOS or INMB?

Which has higher valuation and earnings, ABOS or INMB?

Does the media favor ABOS or INMB?

Do insiders and institutionals have more ownership in ABOS or INMB?

Summary

How does INmune Bio compare to Protalix BioTherapeutics?

Do institutionals & insiders have more ownership in INMB or PLX?

Is INMB or PLX more profitable?

Do analysts recommend INMB or PLX?

Which has preferable earnings & valuation, INMB or PLX?

Does the media favor INMB or PLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools